CAR-T cells have revolutionized clinical therapy, but their application in solid tumors is hindered by various challenges such as mutated antigens, physical barriers, and the tumor microenvironment. The conventional CAR structure has limitations including on-target/off-tumor effects, weak CD3? motif activation, and cytokine release syndrome. Researchers are exploring new avenues to develop CAR-T cells, including specific tumor-associated antigens, costimulatory signaling, and distinct immune cells.
Recent breakthroughs in CAR-T research include single-cell sequencing to determine CAR-T cell differentiation and location and CRISPR-engineered CAR-T cells with improved resistance to immunosuppression. Moreover, Cytokines and their receptors can be harnessed to enhance cytotoxicity. In addition, nanomaterials can work in tandem with CAR-T cells to mitigate off-target effects and restore sensitivity to immune checkpoint inhibitors. Although the efficacy of these cutting-edge technologies is still under evaluation, collecting research results will help determine standard modifications.
Our aim is to gather the latest progress in CAR engineering, emphasizing the innovation and necessity of CAR-T cell therapy to inspire the design of off-the-shelf CAR-T cells. Subtopics of interest include but are not limited to the following:
1) Promotion of novel biomaterials and nanotechnology on CAR-T cells;
2) Gene editing technology enhances the immune function of CAR-T cells;
3) Regulation of CAR-T Cells by Aberrant Metabolism in the Tumor Microenvironment;
4) Detection of distribution of CAR-T cells and management of adverse reactions.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
CAR-T cells have revolutionized clinical therapy, but their application in solid tumors is hindered by various challenges such as mutated antigens, physical barriers, and the tumor microenvironment. The conventional CAR structure has limitations including on-target/off-tumor effects, weak CD3? motif activation, and cytokine release syndrome. Researchers are exploring new avenues to develop CAR-T cells, including specific tumor-associated antigens, costimulatory signaling, and distinct immune cells.
Recent breakthroughs in CAR-T research include single-cell sequencing to determine CAR-T cell differentiation and location and CRISPR-engineered CAR-T cells with improved resistance to immunosuppression. Moreover, Cytokines and their receptors can be harnessed to enhance cytotoxicity. In addition, nanomaterials can work in tandem with CAR-T cells to mitigate off-target effects and restore sensitivity to immune checkpoint inhibitors. Although the efficacy of these cutting-edge technologies is still under evaluation, collecting research results will help determine standard modifications.
Our aim is to gather the latest progress in CAR engineering, emphasizing the innovation and necessity of CAR-T cell therapy to inspire the design of off-the-shelf CAR-T cells. Subtopics of interest include but are not limited to the following:
1) Promotion of novel biomaterials and nanotechnology on CAR-T cells;
2) Gene editing technology enhances the immune function of CAR-T cells;
3) Regulation of CAR-T Cells by Aberrant Metabolism in the Tumor Microenvironment;
4) Detection of distribution of CAR-T cells and management of adverse reactions.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
